SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Jordi Remon

Jordi Remon

HM CIOCC Barcelona, Barcelona

Dr. Jordi Remon is a thoracic medical oncologist at HM CIOCC Barcelona (Centro Integral Oncológico Clara Campal) in Spain, having returned in 2025 from Gustave Roussy in Villejuif, France, where he was a consultant in thoracic oncology. His work centres on non-small-cell lung cancer, with a focus on immunotherapy and targeted therapy for EGFR-mutant disease, as well as mesothelioma and thymic malignancies; he has contributed to EORTC trials including the APPLE study of osimertinib in EGFR-mutant NSCLC. He chairs the EORTC Lung Cancer Group and is a frequent speaker and discussant at major international congresses such as the World Conference on Lung Cancer.

Connect

Jordi Remon

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates